Amgen’s stock falls as analyst warns that hype around obesity drug is baked in
Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.
Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.
